Hypertension
Conditions
Interventions
-Olmesartan 40mg -Once daily -Treatment period: 8 months
-Olmesartan 20mg and Eplerenone 50mg -Once daily -Treatment period: 8 months
Sponsors
Showa University Northern Yokohama Hospital.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) ischemic heart disease patients 2) clinic SBP >=130 mmHg and/or DBP >=80 mmHg 3) ability of oral administration 4) male or female subjects over 20 years of age and under 85 years of age at the time of informed consent 5) eGFR >= 50 ml/min/1.73m2 6) serum potassium < 5.0 mEq/L 7) ability to provide written informed consent
Exclusion criteria
Exclusion criteria: 1) myocardial infarction 2) subjects who already have Olmesartan or Eplerenone at the entry 3) history of allergy against these drugs or similar compounds 4) subjects whose serum potassium level is over 5.0mEq/L 5) Diabetes mellitus patients whose albumin excretion rates > 300mg/24hours 6) subjects with moderate renal dysfunction (eGFR <50 ml/min/1.73m2) 7) hepatic dysfunction (Child-Pugh C) 8) subjects taking potassium supplements, potassium saving diuretics, or strong CYP3A4-inhibitors (Itraconazol, Ritonavir, and Nelfinavir) 9) Pregnancy 10) Additionally, patient who judged that doctor in charge is improper (For example, FH or secondary hyperlipidemia, tumor, administering cyclosporine, drug abuse or alcoholism, hypothyroidism and inherited stripe disease or the family medical histories, previous history of medicinal muscle disorder.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Central blood pressure -Left ventricular mass index (LVMI) -Plasma aldosterone concentration (PAC) | — |
Secondary
| Measure | Time frame |
|---|---|
| -Casual blood pressure (SBP and DBP) -Plasma renin activity -LVEDP -Left atrial dimension, E/A, and E/E' ration seen by echo-cardiographic measurement -Urine albumin -Pulse Wave Velocity -ECG | — |
Countries
Japan
Outcome results
None listed